UNC Lineberger Comprehensive Cancer Center
430
77
103
240
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.0%
60 terminated/withdrawn out of 430 trials
80.0%
-6.6% vs industry average
1%
3 trials in Phase 3/4
49%
118 of 240 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (430)
Tirzepatide in Obesity-Driven Endometrial Cancer
Role: lead
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
Role: lead
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Role: lead
Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
Role: lead
Impact of Financial Incentives
Role: lead
NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma
Role: lead
Dissemination of BREASTChoice AIM1-B
Role: lead
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
Role: lead
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
Role: lead
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Role: lead
Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case Repts
Role: lead
Keep Social Randomized Controlled Trial for Young Adults With Cancer
Role: lead
Study of Trilaciclib and Lurbinectidin
Role: lead
Feasibility Pilot of AYA-PARTNER
Role: lead
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Role: lead
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Role: lead
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
Role: lead
Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT
Role: lead
Digital Art Therapy for Young Cancer Survivors
Role: lead
The STRONG Nutrition Support Study for People With Pancreatic Cancer
Role: lead